Science

Mar 1, 2025, 10:17

Myeloma Paper of the Day, March 1st, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Bone marrow NK cell profile predicts MRD negativity in myeloma patients treated with dara-based therapy; low proportion of CD16+ BM NK cells with decreased cytokine production and degranulation associated with reduced MRD-negativity.”

“The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy”

Authors: Charlotte Korst, Sabrin Tahri, Carolien Duetz, Tom Cupedo, Niels van de Donk et al.

More posts featuring Robert Orlowski.

cancer Carolien Duetz Charlotte Korst Daratumumab multiple myeloma Myeloma Paper of the Day Niels van de Donk OncoDaily Oncology Robert Orlowski Sabrin Tahri Tom Cupedo

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more